{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:54:58Z","timestamp":1790902498603,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ero.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EULAR Rheumatology Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ero.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T12:20:08Z","timestamp":1775823608000},"page":"100154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk-benefit considerations for antirheumatic drug use in pregnancy, breastfeeding, and male preconception: expert perspectives"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-5766","authenticated-orcid":false,"given":"Andrea","family":"Pluma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"R\u00fcegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvette","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"F\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ero.2026.03.002_bib0001","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2665-9913(24)00096-1","article-title":"The outcomes of children born to mothers with autoimmune rheumatic diseases","volume":"6","author":"Andreoli","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.ero.2026.03.002_bib0002","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ero.2026.03.002_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ero.2026.03.002_bib0004","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1093\/rheumatology\/keac262","article-title":"Changes to expert opinion in the use of antirheumatic drugs before and during pregnancy five years after EULAR: points to consider","volume":"61","author":"Ramoni","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ero.2026.03.002_bib0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ard.2025.02.021","article-title":"Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations","volume":"84","author":"Pluma","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ero.2026.03.002_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1353293","article-title":"Real-world pharmacological treatment of pregnant patients with rheumatic diseases from China: a retrospective analysis from 2016 to 2021","volume":"15","author":"Jia","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ero.2026.03.002_bib0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/14712598.2024.2442452","article-title":"Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE project","volume":"25","author":"Lopes","year":"2025","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.ero.2026.03.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.10504","article-title":"Use of biologics during pregnancy among patients with autoimmune conditions","volume":"8","author":"Ewig","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ero.2026.03.002_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X251350087","article-title":"Impact of conflicting information on the use of antirheumatic drugs in pregnancy and breastfeeding: perspectives of healthcare providers from the global PRAISE survey","volume":"17","author":"Schreiber","year":"2025","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.ero.2026.03.002_bib0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-057988","article-title":"Section on Breastfeeding. Policy statement: breastfeeding and the use of human milk","volume":"150","author":"Meek","year":"2022","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.ero.2026.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard-2023-224032","article-title":"Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)","volume":"82","author":"Perez-Garcia","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ero.2026.03.002_bib0012","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ibd\/izab205","article-title":"Low-dose methotrexate therapy does not affect semen parameters and sperm DNA","volume":"28","author":"Grosen","year":"2022","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.ero.2026.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["EULAR Rheumatology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050708126000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:19:58Z","timestamp":1790900398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050708126000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050708126000388"],"URL":"https:\/\/doi.org\/10.1016\/j.ero.2026.03.002","relation":{},"ISSN":["3050-7081"],"issn-type":[{"value":"3050-7081","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-benefit considerations for antirheumatic drug use in pregnancy, breastfeeding, and male preconception: expert perspectives","name":"articletitle","label":"Article Title"},{"value":"EULAR Rheumatology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ero.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}],"article-number":"100154"}}